Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis

Chinese Medicine (United Kingdom)

Volumn 9, Issue 12, 2014, Pages

  Duval, Florent ^a   Moreno Cuevas, Jorge E ^a   González Garza, María Teresa ^a   Rodríguez Montalvo, Carlos ^a   Cruz Vega, Delia Elva ^a  

^a ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ANDROGRAPHIS PANICULATA; ARTICLE; BERBERIS ARISTATA; BUPLEURUM; BUPLEURUM FALCATUM; CELL ACTIVATION; COFFEA; CURCUMA LONGA; EXTRACELLULAR MATRIX; GINKGO BILOBA; GINSENG; GLYCYRRHIZA GLABRA; HUMAN; LIVER FIBROSIS; MEDICINAL PLANT; MEDLINE; NONHUMAN; OXIDATIVE STRESS; SALVIA MILTIORRHIZA; SCUTELLARIA BAICALENSIS; SILYBUM MARIANUM; STELLATE CELL; SYSTEMATIC REVIEW;

EID: 84923054566     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/s13020-014-0027-4     Document Type: Article

References (202)

1. Mormone E, George J, Nieto N: Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011, 193:225-231.
2. Ellis EL, Mann DA: Clinical evidence for the regression of liver fibrosis. J Hepatol 2012, 56:1171-1180.
3. Sánchez-Valle V, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N: Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem 2012, 19:4850-4860.
4. Friedman SL: Liver fibrosis -from bench to bedside. J Hepatol 2003, 38:S38-S53.
5. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Vogel A, Capron F, Chedid A, Bedossa P, PANFIBROSIS Group: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257-265.
6. Lim YS, Kim WR: The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008, 12:733-746.
7. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115:209-218.
8. Reeves HL, Friedman SL: Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 2002, 7:d808-d826.
9. Henderson NC, Iredale JP: Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007, 112:265-280.
10. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
11. Rockey DC: Translating and understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol 2013, 11:224-231.
12. Friedman SL: Hepatic stellate cells: Protean, multifunctional and enigmatic cells of the liver. Physiol Rev 2008, 88:125-172.
13. Lee UE, Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011, 25:195-206.
14. Jiao J, Friedman SL, Aloman C: Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
15. Friedman SL: Hepatic fibrosis -role of hepatic stellate cell activation. Med Gen Med 2002, 4:27.
16. Bachem MG, Melchior R, Gressner AM: The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultures rat liver fat storing cells. J Clin Chem Clin Biochem 1989, 27:555-565.
17. Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJ, Arthur MJ: Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology 1995, 22:304-315.
18. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176.
19. Pinzani M, Marra F: Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001, 21:397-416.
20. Mauviel A: Transforming growth factor-β: a key mediator of fibrosis. Meth Mol Med 2005, 117:69-80.
21. George J, Roulot D, Koteliansky VE, Bissell DM: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Aca Sci USA 1999, 96:12719-12724.
22. Grotendorst GR: Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997, 8:171-179.
23. Rockey DC: Vascular mediators in the injured liver. Hepatology 2003, 37:4-12.
24. Attia YM, Elalkamy EF, Hammam OA, Mahmoud SS, El-Khatib AS: Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection. Parasit Vectors 2013, 6:199.
25. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, Benedetti A: Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996, 23:1189-1199.
26. Calleja MA, Vieites JM, Montero-Meterdez T, Torres MI, Faus MJ, Gil A, Suárez A: The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation. Br J Nutr 2013, 109:394-401.
27. Xu J, Fu Y, Chen A: Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 2003, 285:G20-G30.
28. Zheng S, Chen A: Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004, 384:149-157.
29. He YJ, Shu JC, Lü X, Fang L, Sheng Y: Prophylactic effect of curcumin on hepatic fibrosis and its relationship with activated hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2006, 14:337-340.
30. Cheng Y, Ping J, Xu LM: Effects of curcumin on peroxisome proliferatoractivated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells. Chin Med J 2007, 120:794-801.
31. Shu JC, He YJ, Lv X, Ye GR, Wang LX: Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J Nat Med 2009, 63:415-420.
32. Wu SJ, Tam KW, Tsai YH, Chang CC, Chao JC: Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats. Am J Chin Med 2010, 38:99-111.
33. Lin J, Tang Y, Kang Q, Feng Y, Chen A: Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol 2012, 166:2212-2227.
34. Yao QY, Xu BL, Wang JY, Liu HC, Zhang SC, Tu CT: Inhibition by curcumin of multiples sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complement Altern Med 2012, 12:156.
35. Park SD, Jung JH, Lee HW, Kwon YM, Chung KH, Kim MG, Kim CH: Zedoariae rhizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol 2005, 5:555-569.
36. Chen A, Zheng S: Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. Br J Pharmacol 2008, 153:557-567.
37. 4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008, 73:399-409.
38. 4 in rats: role of TGF-beta modulation and oxidative stress. Fundam Clin Pharmacol 2008, 22:417-427.
39. Tang Y, Zheng S, Chen A: Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signalin. Endocrinology 2009, 150:3011-3020.
40. Kang Q, Chen A: Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol 2009, 157:1354-1367.
41. Kang Q, Chen A: Curcumin eliminates oxidized LDL roles in activating hepatic stellate ells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Invest 2009, 89:1275-1290.
42. Lin J, Zheng S, Chen A: Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab Invest 2009, 89:1397-1409.
43. Morsy MA, Abdalla AM, Mahmoud AM, Abdelwahab SA, Mahmoud ME: Protective effects of curcumin, a-lipoic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats. J Physiol Biochem 2012, 68:29-35.
44. Tu CT, Yao QY, Xu BL, Wang JY, Zhou CH, Zhang SC: Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. Food Chem Toxicol 2012, 50:3343-3351.
45. Yao Q, Lin Y, Li X, Shen X, Wang J, Tu C: Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. Toxicol Lett 2013, 222:72-82.
46. Cheng Y, Ping J, Liu C, Tan YZ, Chen GF: Study on effects of extracts from Salvia Miltiorrhiza and Curcuma Longa in inhibiting phosphorylated extracellular signal regulated kinase expression in rat's hepatic stellate cells. Chin J Integr Med 2006, 12:207-211.
47. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D: Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001, 35:392-398.
48. Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS: Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis. World J Gastroenterol 2005, 11:1141-1148.
49. Hsu YC, Lin YL, Chiu YT, Shiao MS, Lee CY, Huang YT: Antifibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats. J Biomed Sci 2005, 12:185-195.
50. Chen IS, Chen YC, Chou CH, Chuang RF, Sheen LY, Chiu CH: Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J Sci Food Agric 2012, 92:1441-1447.
51. El-Lakkany NM, Hammam OA, El-Maadawy WH, Badawy AA, Ain-Shoka AA, Ebeid FA: Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors 2012, 5:9.
52. Li CC, Hsiang CY, Wu SL, Ho TY: Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-?B bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol 2012, 50:1568-1575.
53. Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI: Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. Int J Mol Med 2012, 30:473-479.
54. Tzeng JI, Chen MF, Chung HH, Cheng JT: Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride. Phytother Res 2013, 27:1023-1028.
55. Ding J, Yu J, Wang C, Hu W, Li D, Luo Y, Luo H, Yu H: Ginkgo biloba extract alleviates liver fibrosis induced by CCl in rats. Liver Int 2005, 25:1224-1232.
56. Liu SQ, Yu JP, He L, Yu HG, Luo HS: Effects of nuclear factor kappaB and transforming growth factor beta1 in the anti-liver fibrosis process using Ginkgo biloba extract. Zhonghua Gan Zang Bing Za Zhi 2005, 13:903-907.
57. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG: Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med 2006, 34:99-114.
58. He SX, Luo JY, Wang YP, Wang YL, Fu H, Xu JL, Zhao G, Liu EQ: Effects of extract from Ginkgo biloba on carbon tetrachloride-induced liver injury in rats. World J Gastroenterol 2006, 12:3924-3928.
59. Zhang C, Zhu Y, Wan J, Xu H, Shi H, Lu X: Effects of Ginkgo biloba extract on cell proliferation, cytokines and extracellular matrix of hepatic stellate cells. Liver Int 2006, 26:1283-1290.
60. Zhang CF, Zhang CQ, Zhu YH, Wang J, Xu HW, Ren WH: Ginkgo biloba extract EGb 761 alleviates hepatic fibrosis and sinusoidal microcirculation disturbance in patients with chronic hepatitis B. Gastroen Res 2008, 1:20-28.
61. Zhang XL, Liu L, Jiang HQ: Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation. World J Gastroenterol 2002, 8:515-519.
62. Chor SY, Hui AY, To KF, Chan KK, Go YY, Chan HL, Leung WK, Sung JJ: Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. J Ethnopharmacol 2005, 100:180-186.
63. Lin YL, Lee TF, Huang YJ, Huang YT: Antiproliferative effect of salvianolic acid A on rat hepatic stellate cells. J Pharm Pharmacol 2006, 58:933-939.
64. Fang SM, Li CS, An JY, Dun ZN, Yao DM, Liu L, Zhang XL: The role of extracellular signal-regulated kinase in induction of apoptosis with salvia miltiorrhiza monomer IH764-3 in hepatic stellate cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2011, 27:402-406.
65. Liu L, Wei J, Huo X, Fang S, Yao D, Gao J, Jiang H, Zhang X: The Salvia miltiorrhiza monomer IH764-3 induces apoptosis of hepatic stellate cells in vivo in a bile duct ligation-induced model of liver fibrosis. Mol Med Rep 2012, 6:1231-1238.
66. Wasser S, Ho JM, Ang HK, Tan CE: Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats. J Hepatol 1998, 29:760-771.
67. Shang Q, Zhang D, Guan W: The inhibitory effect in vitro of salvia miltiorrhiza and tetramethyl pyrazine on the growth of fibroblasts. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1998, 12:321-324.
68. Shang Q, Zhang D, Guan W: The influence of salvia miltiorrhiza and tetramethyl pyrazine on DNA content of cicatricial fibroblasts and its cellular cycle. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1998, 12:325-328.
69. Nan JX, Park EJ, Kang HC, Park PH, Kim JY, Sohn DH: Anti-fibrotic effects of a hot-water extract from Salvia miltiorrhiza roots on liver fibrosis induced by biliary obstruction in rats. J Pharm Pharmacol 2001, 53:197-204.
70. Wang YM, Wei FK, Liu M: Effect of Salvia miltiorrhiza on autocrining growth factor by fibroblasts cultured in vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2002, 16:408-410.
71. Lay IS, Chiu JH, Shiao MS, Lui WY, Wu CW: Crude extract of Salvia miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in murine SVR endothelial cell line. Planta Med 2003, 69:26-32.
72. Wang JM, Yao XX, Li XT, Yang SL, Su Z: Effects of Radix Salviae Miltiorrhizae on Ca2+ in hepatic stellate cells. Sichuan Da Xue Xue Bao Yi Xue Ban 2005, 36:221-224.
73. Yao XX, Lv T: Effects of pharmacological serum from normal and liver fibrotic rats on HSCs. World J Gastroenterol 2005, 11:2444-2449.
74. Lv T, Yao XX: Comparison of protocatechuic aldchyde in Radix Salvia miltiorrhiza and corresponding pharmacological sera from normal and fibrotic rats by high performance liquid chromatography. World J Gastroenterol 2006, 12:2195-2200.
75. Paik YH, Yoon YJ, Lee HC, Jung MK, Kang SH, Chung SI, Kim JK, Cho JY, Lee KS, Han KH: Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Exp Mol Med 2011, 43:341-349.
76. Sferra R, Vetuschi A, Catitti V, Ammanniti S, Pompili S, Melideo D, Frieri G, Gaudio E, Latella G: Boswellia serrata and Salvia miltiorrhiza extracts reduce DMN-induced hepatic fibrosis in mice by TGF-beta1 downregulation. Eur Rev Med Pharmacol Sci 2012, 16:1484-1498.
77. Zhang Y, Zhang Y, Xie Y, Gao Y, Ma J, Yuan J, Li J, Wang J, Li L, Zhang J, Chu L: Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by Salvia miltiorrhiza. J Ethnopharmacol 2013, 148:671-681.
78. Sun RF, Liu LX, Zhang HY: Effect of tanshinone II on hepatic fibrosis in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009, 29:1012-1017.
79. Liu J: The effect of IH764-3 on proliferation and function of fibroblasts. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1993, 15:201-205.
80. Liu L, Jiang HQ, Zhang XL: The effect and mechanism of Salvia miltiorrhiza monomer IH764-3 on proliferation and collagen synthesis of hepatic stellate cells stimulated by H2O2. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2003, 19:78-81.
81. Liu J, Hua G, Liu W, Cui Y, Huang H, Zhao S, Chu Y, Yang C, Chen W: The effect of IH764-3 on fibroblast proliferation and function. Chin Med Sci J 1992, 7:142-147.
82. Liu CH, Liu P, Hu YY, Xu LM, Tan YZ, Wang ZN, Liu C: Effects of salvianolic acid-A on rat hepatic stellate cell proliferation and collagen production in culture. Acta Pharmacol Sin 2000, 21:721-726.
83. Liu C, Liu P, Hu Y, Zhu D: Effects of salvianolic acid-B on TGF-beta 1 stimulated hepatic stellate cell activation and its intracellular signaling. Zhonghua Yi Xue Za Zhi 2002, 82:1267-1272.
84. Lin YL, Wu CH, Luo MH, Huang YJ, Wang CN, Shiao MS, Huang YT: In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. J Ethnopharmacol 2006, 105:215-222.
85. Wang R, Yu XY, Guo ZY, Wang YJ, Wu Y, Yuan YF: Inhibitory effects of salvianolic acid B on CCl(4)-induced hepatic fibrosis through regulating NF-κB/I?Ba signaling. J Ethnopharmacol 2012, 144:592-598.
86. Hu Y, Wang R, Zhang X, Liu C, Liu C, Liu P, Zhu D: Effects of carbon tetrachloride-injured hepatocytes on hepatic stellate cell activation and salvianolic acid A preventive action in vitro. Zhonghua Gan Zang Bing Za Zhi 2000, 8:299-301.
87. Liu CH, Hu YY, Wang XL, Liu P, Xu LM: Effects of salvianolic acid-A on NIH/3 T3 fibroblast proliferation, collagen synthesis and gene expression. World J Gastroenterol 2000, 6:361-364.
88. Liu P, Liu CH, Wang HN, Hu YY, Liu CC: Effect of salvianolic acid B on collagen production and mitogen-activated protein kinase activity in rat hepatic stellate cells. Acta Pharmacol Sin 2002, 23:733-738.
89. Zhao JF, Liu CH, Hu YY, Xu LM, Liu P, Liu C: Effect of salvianolic acid B on Smad3 expression in hepatic stellate cells. Hepatobiliary Pancreat Dis Int 2004, 3:102-105.
90. Xue DY, Hong JH, Xu LM: Salianic-acid B inhibits MAPK signaling in activated rat hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2004, 12:471-474.
91. Wang XN, Hu YY, Liu CH, Liu P, Zhu DY: Effects of salvianolic acid B on expressions of TGF-beta1 and its receptors in liver of rats with dimethylnitrosamine-induced hepatic fibrosis. Zhong Xi Yi Jie He Xue Bao 2005, 3:286-289.
92. Xue DY, Hong JH, Xu LM: Effects of salvianolic acid B on signal transduction induced by transforming growth factor-beta1 and platelet-derived growth factor-BB in hepatic stellate cells of rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006, 26:439-442.
93. Zhang J, Zhang WW, Xu LM: Effect and mechanism of salvianolic-acid B on inhibiting endothelin-1-induced contraction of human hepatic stellate cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009, 29:60-64.
94. Lv Z, Song Y, Xue D, Zhang W, Cheng Y, Xu L: Effect of salvianolic-acid B on inhibiting MAPK signaling induced by transforming growth factor-β1 in activated rat hepatic stellate cells. J Ethnopharmacol 2010, 132:384-392.
95. Tsai MK, Lin YL, Huang YT: Differential inhibitory effects of salvianolic acids on activation of rat hepatic stellate cells by platelet-derived growth factor. Planta Med 2011, 77:1495-1503.
96. Song YF, Lü ZG, Xu LM: Salvianolic acid B inhibits ERK signal transduction pathway activated by transforming growth factor-β1 in rat hepatic stellate cells. Zhong Xi Yi Jie He Xue Bao 2012, 10:454-461.
97. Xu H, Zhou Y, Lu C, Ping J, Xu LM: Salvianolic acid B lowers portal pressure in cirrhotic rats and attenuates contraction of rat hepatic stellate cells by inhibiting RhoA signaling pathway. Lab Invest 2012, 92:1738-1748.
98. Li S, Wang L, Yan X, Wang Q, Tao Y, Li J, Peng Y, Liu P, Liu C: Salvianolic acid B attenuates rat hepatic fibrosis via downregulating angiotensin II signaling. Evid Based Complement Alternat Med 2012, 2012:160726.
99. Song YF, Lv ZG, Xu LM: Effects of salvianolic-acid B on the p38MAPK signaling pathway and its transcriptional factor induced by transforming growth factor b1 in activated rat hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2012, 20:902-907.
100. Lv Z, Xu L: Salvianolic Acid B inhibits ERK and p38 MAPK signaling in TGF-β1-stimulated human hepatic stellate lell line (LX-2) via distinct pathways. Evid Based Complement Altern Med 2012, 2012:960128.
101. Qu Y, Chen WH, Zong L, Xu MY, Lu LG: 18a-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells. Med Sci Monit 2012, 18:BR24-BR32.
102. Dong L, Sun JY, Fang GT, Jiang LD, Wang JY: Effects of glycyrrhizin on TGFbeta1 stimulated hepatic stellate cell signaling transduction. Zhonghua Gan Zang Bing Za Zhi 2005, 13:828-831.
103. Moro T, Shimoyama Y, Kushida M, Hong YY, Nakao S, Higashiyama R, Sugioka Y, Inoue H, Okazaki I, Inagaki Y: Glycyrrhizin and its metabolite inhibit Smad3-mediated type I collagen gene transcription and suppress experimental murine liver fibrosis. Life Sci 2008, 83:531-539.
104. Wang JY, Zhang QS, Guo JS, Hu MY: Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats. World J Gastroenterol 2001, 7:115-119.
105. Li X, Peng XD, Zhang WL, Dai LL: Inhibiting effects of denshensu, baicalin, astragalus and Panax notoginseng saponins on hepatic fibrosis and their possible mechanisms. Zhonghua Gan Zang Bing Za Zhi 2008, 16:193-197.
106. Peng XD, Dai LL, Huang CQ, He CM, Chen LJ: Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. World J Gastroenterol 2009, 15:4720-4725.
107. Qiao H, Han H, Hong D, Ren Z, Chen Y, Zhou C: Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPAR? and inhibiting TGFβ1. Pharm Biol 2011, 49:38-45.
108. Fan J, Li X, Li P, Li N, Wang T, Shen H, Siow Y, Choy P, Gong Y: Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol 2007, 85:189-195.
109. Wang X, Wang Q, Burczynski FJ, Kong W, Gong Y: Saikosaponin A of Bupleurum chinense (Chaihu) elevates bone morphogenetic protein 4 (BMP-4) during hepatic stellate cell activation. Phytomedicine 2013, 20:1330-1335.
110. Suresh V, Asha VV: Preventive effect of ethanol extract of Phyllanthus rheedii Wight. on D-galactosamine induced hepatic damage in Wistar rats. J Ethnopharmacol 2008, 116:447-453.
111. Amin ZA, Alshawsh MA, Kassim M, Ali HM, Abdulla MA: Gene expression profiling reveals underlying molecular mechanism of hepatoprotective effect of Phyllanthus niruri on thioacetamide-induced hepatotoxicity in Sprague Dawley rats. BMC Complement Altern Med 2013, 13:160.
112. Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, Wang H: Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol 2008, 35:303-309.
113. Sun X, Zhang X, Hu H, Lu Y, Chen J, Yasuda K, Wang H: Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fibrosis. Biol Pharm Bull 2009, 32:1533-1537.
114. 4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. J Med Food 2013, 16:518-528.
115. Wu YL, Wan Y, Jin XJ, OuYang BQ, Bai T, Zhao YQ, Nan JX: 25-OCH3-PPD induces the apoptosis of activated t-HSC/Cl-6 cells via c-FLIP-mediated NF-κB activation. Chem Biol Interact 2011, 194:106-112.
116. Geng J, Peng W, Huang Y, Fan H, Li S: Ginsenoside-Rg1 from Panax notoginseng prevents hepatic fibrosis induced by thioacetamide in rats. Eur J Pharmacol 2010, 634:162-169.
117. Lo YT, Tsai YH, Wu SJ, Chen JR, Chao JC: Ginsenoside Rb1 inhibits cell activation and liver fibrosis in rat hepatic stellate cells. J Med Food 2011, 14:1135-1143.
118. Peng XD, Dai LL, Huang CQ, He CM, Yang B, Chen LJ: Relationship between anti-fibrotic effect of Panax notoginseng saponins and serum cytokines in rat hepatic fibrosis. Biochem Biophys Res Commun 2009, 388:31-34.
119. Lee TY, Lee KC, Chang HH: Modulation of the cannabinoid receptors by andrographolide attenuates hepatic apoptosis following bile duct ligation in rats with fibrosis. Apoptosis 2010, 15:904-914.
120. Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM: Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol 2008, 49:758-767.
121. Gressner OA: About coffee, cappuccino and connective tissue growth factor-Or how to protect your liver? Environ Toxicol Pharmacol 2009, 28:1-10.
122. Shi H, Dong L, Zhang Y, Bai Y, Zhao J, Zhang L: Protective effect of a coffee preparation (Nescafe pure) against carbon tetrachloride-induced liver fibrosis in rats. Clin Nutr 2010, 29:399-405.
123. Shin JW, Wang JH, Kang JK, Son CG: Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. J Sci Food Agric 2010, 90:450-455.
124. Klemmer I, Yagi S, Gressner OA: Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis. Hepatol Res 2011, 41:1094-1109.
125. Furtado KS, Prado MG, Aguiar E, Silva MA, Dias MC, Rivelli DP, Rodrigues MA, Barbisan LF: Coffee and caffeine protect against liver injury induced by thioacetamide in male Wistar rats. Basic Clin Pharmacol Toxicol 2012, 111:339-347.
126. Arauz J, Moreno MG, Cortés-Reynosa P, Salazar EP, Muriel P: Coffee attenuates fibrosis by decreasing the expression of TGF-β and CTGF in a murine model of liver damage. J Appl Toxicol 2013, 33:970-979.
127. Shim SG, Jun DW, Kim EK, Saeed WK, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC: Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol 2013, 28:1877-1884.
128. Arauz J, Zarco N, Segovia J, Shibayama M, Tsutsumi V, Muriel P: Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β. Eur J Gastroenterol Hepatol 2013, 26:164-173.
129. Gressner OA, Siluschek M, Lahme B, Gressner AM: Intraperitoneal application of caffeine prevents D-galactosamine-induced hepatic expression of connective tissue growth factor (CTGF/CCN2) in the rat. J Hepatol 2009, 50:1053-1055.
130. Gressner OA, Lahme B, Siluschek M, Gressner AM: Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in liver parenchymal cells. Liver Int 2009, 29:886-897.
131. Rockey DC: Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008, 12:939-962.
132. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G: Expression of matrix metalloproteinases and their inhibitor during hepatic tissue repair in rat. Histochem Cell Biol 2000, 113:443-453.
133. Benyon RC, Arthur MJ: Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001, 21:373-384.
134. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002, 277:11069-11076.
135. Knittel T, Fellmer P, Ramadori G: Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver. Gastroenterology 1996, 111:745-754.
136. Zhang LP, Takahara T, Yata Y, Furui K, Jin B, Kawada N, Watanabe A: Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999, 31:703-711.
137. Fibbi G, Pucci M, Grappone C, Pellegrini G, Salzano R, Casini A, Milani S, Del Rosso M: Functions of the fibrinolytic system in human Ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology 1999, 29:868-878.
138. Wynn TA, Barron L: Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010, 30:245-257.
139. Hironaka K, Sakaida I, Matsumura Y, Kaino S, Miyamoto K, Okita K: Enhanced interstitial collagenase (Matrix metalloproteinase-13) production of Kupffer cell by gadolimium chloride prevents pig serum-induced rat liver fibrosis. Biochem Biophys Res Commun 2000, 267:290-295.
140. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, Iredale JP: Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007, 178:5288-5295.
141. Friedman SL: Mac the knife? Macrophages: the double-edged sword of hepatic fibrosis. J Clin Invest 2005, 115:29-32.
142. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G: Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-a and TGF-β1. J Hepatol 1999, 30:48-60.
143. Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC: Classical macrophage activation up-regulates several matrix metalloproteinase's through mitogen activated protein kinases and nuclear factor-?B. PLoS One 2012, 7:e42507.
144. Fallowfield JA: Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011, 300:G709-G715.
145. Siller-López F, Sandoval A, Salgado S, Salazar A, Bueno M, Garcia J, Vera J, Gálvez J, Hernández I, Ramos M, Aguilar-Cordova E, Armendariz-Borunda J: Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004, 126:1122-1133.
146. Iimuro Y, Nishio T, Morimoto T, Nitta Tm Stefanovic B, Choi SK, Brenner DA, Yamaoka Y: Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003, 124:445-458.
147. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Grötzinger J, Gressner AM, Matern S, Roeb E: Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006, 20:444-454.
148. Bueno M, Salgado S, Beas-Zárate C, Armendariz-Borunda J: Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. J Gene Med 2006, 8:1291-1299.
149. Lin YL, Lin CY, Chi CW, Huang YT: Study on antifibrotic effects of curcumin in rat hepatic stellate cells. Phytother Res 2009, 23:927-932.
150. Kang HC, Nan JX, Park PH, Kin JY, Lee SH, Woo SW, Zhao YZ, Park EJ, Sohn DH: Curcumin inhibits collagen synthesis and hepatic stellate cell activation in-vivo and in-vitro. J Pharm Pharmacol 2002, 54:119-126.
151. Yang W, Chen H, Jiang Y: Inhibitive effect of curcumin and amiloride on the fibrosis of rat hepatic stellate cells induced by oxidative stress. Zhong Yao Cai 2003, 26:795-798.
152. Zheng S, Chen A: Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am J Physiol Gastrointest Liver Physiol 2006, 290:G883-G893.
153. Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H, Genina O, Helpern Z, Pines M: Prevention of liver cirrhosis in rats by curcumin. Liver Int 2007, 27:373-383.
154. Cheng Y, Ping J, Liu C: Effect of curcumin on activity of matrix metalloproteinase 2, 9 and nuclear expression of RelA in rat hepatic stellate cells by activating peroxisome proliferator-activated receptor gamma signal. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007, 27:439-443.
155. Shu JC, Ye GR, Lü X, Fang L, Wu HE, Chen XJ: Therapeutic effects of curcumin treatment on hepatic fibrosis. Zhonghua Gan Zang Bing Za Zhi 2007, 15:753-757.
156. Vizzutti F, Provenzano A, Galastri S, Milani S, Delogu W, Novo E, Caligiuri A, Zamara E, Arena U, Laffi G, Parola M, Pinzani M, Marra F: Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 2010, 90:104-115.
157. Pinlaor S, Prakobwong S, Hiraku Y, Pinlaor P, Laothong U, Yongvanit P: Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment. Eur J Pharmacol 2010, 638:134-141.
158. Hassan ZK, Al-Olayan EM: Curcumin reorganizes miRNA expression in a mouse model of liver fibrosis. Asian Pac J Canc Prev 2012, 13:5405-5408.
159. Zhang Z, Guo Y, Zhang S, Zhang Y, Wang Y, Ni W, Kong D, Chen W, Zheng S: Curcumin modulates cannabinoid receptors in liver fibrosis in vivo and inhibits extracellular matrix expression in hepatic stellate cells by suppressing cannabinoid receptor type-1 in vitro. Eur J Pharmacol 2013, 721:133-140.
160. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D: Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26:643-649.
161. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM: Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003, 37:336-339.
162. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M: Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009, 50:1102-1111.
163. Shaker ME, Zalata KR, Mehal WZ, Shiha GE, Ibrahim TM: Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. Toxicol Appl Pharmacol 2011, 252:165-175.
164. Ezhilarasan D, Karthikeyan S, Vivekanandan P: Ameliorative effect of silibinin against N-nitrosodimethylamine-induced hepatic fibrosis in rats. Environ Toxicol Pharmacol 2012, 34:1004-1013.
165. Lin YL, Hsu YC, Chiu YT, Huang YT: Antifibrotic effects of a herbal combination regimen on hepatic fibrotic rats. Phytother Res 2008, 22:69-76.
166. 4-induced liver fibrosis in rats. World J Gastroenterol 2004, 10:1037-1042.
167. Li W, Dai QT, Liu ZE: Preliminary study on early fibrosis of chronic hepatitis B treated with Ginkgo biloba Composita. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995, 15:593-595.
168. Sener G, Kabasakal L, Yüksel M, Gedik N, Alican Y: Hepatic fibrosis in biliary-obstructed rats is prevented by Ginkgo biloba treatment. World J Gastroenterol 2005, 11:5444-5449.
169. Huang SZ, Luo YJ, Wang L, Cai KY: Effect of ginkgo biloba extract on livers in aged rats. World J Gastroenterol 2005, 11:132-135.
170. 4-poisoned liver injury and fibrosis in rats. Zhongguo Yao Li Xue Bao 1997, 18:478-480.
171. Lee TY, Wang GJ, Chiu JH, Lin HC: Long-term administration of Salvia miltiorrhiza ameliorates carbon tetrachloride-induced hepatic fibrosis in rats. J Pharm Pharmacol 2003, 55:1561-1568.
172. Oh SH, Cho KH, Yang BS, Roh YK: Natural compounds from Danshen suppress the activity of hepatic stellate cells. Arch Pharm Res 2006, 29:762-767.
173. Zhang L, Wu T, Chen JM, Yang LL, Song HY, Ji G: Danshensu inhibits acetaldehyde-induced proliferation and activation of hepatic stellate cell-T6. Zhong Xi Yi Jie He Xue Bao 2012, 10:1155-1161.
174. Tsai MK, Lin YL, Huang YT: Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol 2010, 242:155-164.
175. Wang L, Tao Y, Li S, Chen G, Liu C: Effects of salvianolic acid B on lipid peroxidation and metalloproteinase-2 activity in fibrotic liver in rat. Zhongguo Zhong Yao Za Zhi 2010, 35:71-75.
176. Hou J, Tian J, Jiang W, Gao Y, Fu F: Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis. Eur J Pharmacol 2011, 650:390-395.
177. Tao YY, Wang QL, Shen L, Fu WW, Liu CH: Salvianolic acid B inhibits hepatic stellate cell activation through transforming growth factor beta-1 signal transduction pathway in vivo and in vitro. Exp Biol Med (Maywood) 2013, 238:1284-1296.
178. Liu L, Jiang HQ, Zhang XL, Zhao DQ: Effect of Salvia miltiorrhiza monomer IH764-3 on MMP-13 and TIMP-1 by downregulating the expression of focal adhesion kinase in hepatic stellate cell stimulated by H2O2. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2007, 23:482-486.
179. Yang C: Effect of IH764-3 on prolyl hydroxylation in collagen biosynthesis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1993, 15:364-368.
180. 4-induced hepatocyte apoptosis in rats via a p53-mediated pathway. World J Gastroenterol 2013, 19:3781-3791.
181. Abe K, Ikeda T, Wake K, Sato T, Sato T, Inoue H: Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol 2008, 60:91-97.
182. He Y, Hu ZF, Li P, Xiao C, Chen YW, Li KM, Guo JZ, Pan L, Xiong JP: Experimental study of saikosaponin-D (SSd) on lipid peroxidation of hepatic fibrosis on rat. Zhongguo Zhong Yao Za Zhi 2008, 33:915-919.
183. Surya Narayanan B, Latha P, Rukkumani R: Protective effects of Phyllanthus amarus on fibrotic markers during alcohol and polyunsaturated fatty acid-induced toxicity. Toxicol Mech Methods 2011, 21:48-52.
184. Ki SH, Yang JH, Ku SK, Kim SC, Kim YW, Cho IJ: Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. J Ginseng Res 2013, 37:45-53.
185. Jiang H, Xia LZ, Li Y, Li X, Wu J: Effect of Panax notoginseng saponins on expressions of MMP-13 and TIMP-1 in rats with hepatic fibrosis. Zhongguo Zhong Yao Za Zhi 2013, 38:1206-1210.
186. Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, Fogliano V, Caporaso N, D'Argenio G: Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010, 52:1652-1661.
187. Moreno MG, Chávez E, Aldaba-Muruato LR, Segovia J, Vergara P, Tsutsumi V, Shibayama M, Rivera-Espinoza Y, Muriel P: Coffee prevents CCl(4)-induced liver cirrhosis in the rat. Hepatol Int 2011, 5:857-863.
188. Shi H, Dong L, Bai Y, Zhao J, Zhang Y, Zhang L: Chlorogenic acid against carbon tetrachloride-induced liver fibrosis in rats. Eur J Pharmacol 2009, 623:119-124.
189. Shi H, Dong L, Jiang J, Zhao J, Zhao G, Dang X, Lu X, Jia M: Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway. Toxicology 2013, 303:107-114.
190. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phaseI/II trial. J Gastroenterol Hepatol 1999, 14:1093-1099.
191. van Rossum TG, Vulto AG, Hop WC, Schalm SW: Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001, 96:2432-2437.
192. Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin H, Schalm SW: Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol 2006, 45:539-546.
193. Manns MP, Wedemeyer H, Singer A, Khomutjanskaja N, Dienes HP, Roskams T, Goldin R, Hehnke U, Inoue H, European SNMC, Study Group: Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat 2012, 19:537-546.
194. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ: Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002, 8:679-685.
195. She SF, Huang XZ, Tong GD: Clinical study on treatment of liver fibrosis by different dosages of Salvia injection. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004, 24:17-20.
196. Ye F, Liu Y, Qiu G, Zhao Y, Liu M: Clinical study in treatment of cirrosis by different stages of salvia injection. Zhong Yao Cai 2005, 28:850-854.
197. Jin CX, Yang J, Sun HF: Comparative study of the clinical effects of salvia miltiorrhiza injection and shengmai injection on chronic hepatitis B. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006, 26:936-938.
198. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE, HALT-C Trial Group: Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis. Aliment Pharmacol Ther 2011, 33:127-137.
199. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH: Analysis of silibinin in rat plasma and bile for hepatobiliary excretion nd oral bioavilbility application. J Pharm Biomed Anal 2007, 45:635-641.
200. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW, SyNCH Trial group: Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010, 50:434-449.
201. Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW: Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos 2011, 39:2182-2190.
202. Fried MW, Navrro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR, Silymarin in NASH and C Hepatitis (SyNCH) Study Group: Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unseccessfully treated with interferin therapy: a randomized controlled trial. JAMA 2012, 308:274-282.